T
Tarsus Pharmaceuticals, Inc. (TARS)
NMS – Real Time Price. Currency in USD
59.83
+0.18 (0.30%)
At close: May 12, 2026, 4:00 PM EDT
59.83
0.00 (0.00%)
After-hours: May 12, 2026, 5:13 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
59.83
+0.18 (0.30%)
At close: May 12, 2026, 4:00 PM EDT
59.83
0.00 (0.00%)
After-hours: May 12, 2026, 5:13 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.74 | 6.05 | 10 | |
| Quick ratio | 3.71 | 5.63 | 10 | |
| Debt to Equity | 0.25 | 0.30 | 8.0 | |
| Debt to Assets | 0.15 | 1.04 | 8.0 | |
| Interest coverage | -2.88 | -16.91 | 1.0 | |
| Weighted average score | 7.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 26M | 17M | 183M | 451M | 535M |
| Gross Profit | 25M | 16M | 170M | 421M | 500M |
| Operating Income | -63M | -143M | -121M | -71M | -51M |
| Net Income | -62M | -136M | -116M | -66M | -48M |
| EBITDA | -62M | -142M | -119M | -69M | -49M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 63.01 | 52.71 | 10 |
| Next quarter | 47.94 | 40.96 | 10 |
| Current year | 53.85 | 55.5 | 10 |
| Next year | 30.19 | 516.96 | 10 |
| Weighted average score | 10 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 6.85 | 16.79 | 20 | -334.88 | 6.0 |
| Y/Y | 106.87 | 72.27 | 75 | -43.44 | 7.8 |
| 3y average | 354.31 | -20.44 | -0.51 | -12.55 | 3.3 |
| 5y average | 401.44 | -72.39 | -38.63 | -317.91 | 3.3 |
| Weighted average score | 5.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $102.2M significantly exceed its total debt $88.7M, ensuring strong financial flexibility
Total current assets $537.2M exceed Total current liabilities $143.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.3) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-2.9x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$30.5M limits the company's ability to reinvest or pay down debt